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Folic Acid Supplementation for the Prevention
of Neural Tube Defects
An Updated Evidence Report and Systematic Review
for the US Preventive Services Task Force
Meera Viswanathan, PhD; Katherine A. Treiman, PhD; Julia Kish-Doto, PhD; Jennifer C. Middleton, PhD;
Emmanuel J. L. Coker-Schwimmer, MPH;Wanda K. Nicholson, MD
IMPORTANCE Neural tube defects are among themost common congenital anomalies in the
United States. Periconceptional folic acid supplementation is a primary care–relevant
preventive intervention.
OBJECTIVE Toreviewtheevidenceonfolicacidsupplementationforpreventingneural tubedefects
to inform theUSPreventive Services Task Force for an updatedRecommendation Statement.
DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries through January 28,
2016, with ongoing surveillance through November 11, 2016; references; experts.
STUDY SELECTION English-language studies of folic acid supplementation in women.
Excluded were poor-quality studies; studies of prepubertal girls, men, womenwithout the
potential for childbearing, and neural tube defect recurrence; and studies conducted
in developing countries.
DATA EXTRACTION AND SYNTHESIS Two investigators independently reviewed abstracts,
full-text articles, and risk of bias of included studies. One investigator extracted data and
a second checked accuracy. Because of heterogeneity, data were not pooled.
MAIN OUTCOMES ANDMEASURES Neural tube defects, harms of treatment (twinning,
respiratory outcomes).
RESULTS A total of 24 studies (N > 58860)were included. In 1 randomized clinical trial from
Hungary initiated in 1984, incidenceof neural tubedefects for folic acid supplementation
comparedwith trace element supplementationwas0%vs0.25%(Petoodds ratio [OR],0.13
[95%CI,0.03-0.65]; n = 4862).Odds ratios fromcohort studies recruitingparticipants between
1984and 1996demonstratedbeneficial associations and ranged from0.11 to0.27 (n = 19982).
Threeof4 case-control studieswithdata from 1976 through 1998 reportedORs ranging from0.6
to0.7 (n > 7121). Evidenceof benefit led to food fortification in theUnitedStatesbeginning in
1998, afterwhichnonewprospective studies havebeen conducted.More recent case-control
studies drawing fromdata collected after 1998havenotdemonstrated aprotective association
consistentlywith folic acid supplementation,withORs ranging from0.93 to 1.4 and confidence
intervals spanning thenull (n > 13990). Regardingharms, 1 trial (OR, 1.40 [95%CI,0.89-2.21];
n = 4767) and 1 cohort study (OR, 1.04 [95%CI,0.91-1.18]; n = 2620) foundno statistically
significant increased risk of twinning. Three systematic reviews foundnoconsistent evidenceof
increased risk of asthma (OR, 1.06 [95%CI,0.99-1.14]; n = 14438),wheezing, or allergy.
CONCLUSIONS AND RELEVANCE In studies conducted before the initiation of food fortification
in the United States in 1998, folic acid supplementation provided protection against neural
tube defects. Newer postfortification studies have not demonstrated a protective association
but have the potential for misclassification and recall bias, which can attenuate themeasured
association of folic acid supplementation with neural tube defects.
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N eural tube defects (NTDs) are among themost commoncongenital anomalies in the United States. NTDs occurvery early in the pregnancy,with limited or no chance for
complete recovery. The Centers for Disease Control and Preven-
tionestimatedthat theaverageannualprevalenceof the2mostcom-
mon kinds of NTDs, anencephaly and spina bifida, was 6.5 per
10000 live births for the period from 2009 to 2011.1 Prevention is
an important medical intervention. Periconceptional folic acid
supplementation is a primary prevention intervention that can be
implemented in primary care settings.
In 2009, the US Preventive Services Task Force (USPSTF) rec-
ommendedthatallwomenplanningapregnancyorcapableofpreg-
nancy take adaily supplement containing0.4 to0.8mgof folic acid
(A recommendation). To inform an updated recommendation, the
evidence on benefits and harms of folic acid supplementation in
populations relevant to US primary care was reviewed.
Methods
Scope of the Review
Detailed methods and contextual information (on current intake
of folic acid fromdiet and other sources, effect of folic acid outside
the periconceptional period, variation in benefits by risk factors,
and supplementation benefits other than protection against neu-
ral tube defects) are available in the full evidence report available
athttps://www.uspreventiveservicestaskforce.org/Page/Document
/final-evidence-review146/folic-acid-for-the-prevention-of
-neural-tube-defects-preventive-medication.Figure1showstheana-
lytic framework and key questions (KQs) that guided the review.
Data Sources and Searches
We searched PubMed, the Cochrane Library, and EMBASE for
English-language articles published from database inception
through January 28, 2016. The search strategies for these
databases are listed in the eMethods in the Supplement. Unpub-
lished literature was searched for in ClinicalTrials.gov, HSRProj
(Health Services Research Projects in Progress), the World Health
Organization’s International Clinical Trials Registry Platform, and
NIH Reporter. To supplement electronic searches, the reference
lists of pertinent articles and all suggested citations from peer
reviewers were reviewed. Ongoing surveillance was conducted
after January 2016 through article alerts and targeted searches of
high-impact journals to identify major studies published in the
interim thatmay affect the conclusions or understanding of the evi-
dence and therefore the related USPSTF recommendation. The last
surveillance was conducted on November 11, 2016.
Study Selection
Two investigators independently reviewedtitles, abstracts, and full-
text articlesusingprespecified inclusioncriteria for eachKQ(eTable
1 in the Supplement).
Studies were included if they focused on the use of folic acid
supplementation for the prevention of NTD-affected pregnancies
in women of childbearing age. Not included were studies of prepu-
bertal girls or men or women without the potential for childbearing
(eg, postmenopausal, genetic, uterine, or ovarian abnormalities).
We searched for studies that examined the use of folic acid supple-
mentation with or without food fortification or naturally occurring
folate for the prevention of NTDs.We also searched for studies that
examined the supplementation of micronutrients (eg, multivita-
min, iron) in combinationwith folic acid for the prevention of NTDs.
For all KQs, we searched for studies conducted in the United States
or in countries rated “very high” on the United Nations Human
Development Index.3
Studies were included that compared interventions with pla-
cebo, no treatment, dietary supplementation only, supplementa-
tion with prenatal vitamins without folic acid, or iron supplements
without folic acid for questions on benefits and harms and varia-
tions in subpopulations (KQs 1a, 1b, and 2a). Included studies
Figure 1. Analytic Framework and Key Questions
Key questions
1 a. To what extent does folic acid supplementation reduce the risk for neural tube defects (NTDs)
 (first occurrence) in women of childbearing age?
b. Does the effect of folic acid supplementation on NTDs (first occurrence) differ by race or ethnicity?
c. Do the benefits of folic acid supplementation differ by dosage, timing, or duration of therapy?
2 a. Are there harms associated with folic acid supplementation to the mother, fetus, neonate, or child?
b. Do the harms of folic acid supplementation differ by dosage, timing, or duration of therapy?
Decreased NTD-affected
pregnancies
1
Women of
childbearing age
Serum
folate levels
Folic acid
supplementation
2
Harms of
supplementation
This analytic framework uses USPSTF
iconography and convention.2
Arrows represent linkages in the
evidence chain. Health outcomes are
represented by rectangles with
squared corners and intermediate
outcomes by rectangles with
rounded corners. Curved arrows lead
to ovals representing harms.
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compared interventions with lower or higher dose of folic acid
supplementation only for questions about variations in benefits
and harms by dosage (KQs 1b, 1c, and 2b).
Studies were sought that reported on the benefits of folic acid
supplementation initiatedbefore the indexpregnancyor in the first
trimester to prevent NTDs for questions on benefits and variation
in benefits in subpopulations (KQs 1a and 1b). The timing of the in-
terventionwasexpandedthroughtheendof thepregnancyforques-
tionsontheeffectof timingonbenefitsoranyharmsquestions (KQs
1c, 2a, and 2b).
For benefits and harms (KQs 1 and 2), randomized clinical trials
(RCTs), nonrandomized controlled trials, cohort studies, case-
control studies, and systematic reviews were included. Addition-
ally, for harms (KQs 2a and 2b), registry data were included.
Tworeviewersdually reviewedthequalityofall studies included
inthe2009reportthatmettheinclusioncriteriaforthecurrentreview
and resolveddisagreement bydiscussion and consensus.
Data Extraction andQuality Assessment
For each included study, one investigator extracted information
aboutmethods, patientpopulation, intervention, comparator, out-
comes, timing, setting, and study design, and a second investiga-
tor reviewed for completeness and accuracy. Two independent in-
vestigators assessed thequality of each study as good, fair, or poor,
usingpredefinedcriteriadevelopedby theUSPSTFandadapted for
this topic (eTables 2, 3, 4, and 5 in the Supplement).
Disagreements were resolved by discussion and consensus.
Issues leading to a judgment of poor quality included the risk of
misclassification bias from retrospective recall of level and timing
of exposure; the risk of selection bias from not identifying all
cases of the outcome, including fetal deaths; and the risk of con-
founding from not appropriately accounting for factors such as
infertility that might influence both exposure to folic acid supple-
mentation and the outcome of twinning. Studies with 1 or more of
these features were rated as poor quality. Other flaws that
resulted in poor-quality ratings included initially assembled
groups not close to being comparable or maintained throughout
the study (including overall attrition of at least 20% or differential
attrition of at least 15% between groups); use of unreliable or
invalid measurement instruments or unequal application among
groups (including not masking outcome assessment); and, for
RCTs, the lack of intention-to-treat analysis.
Data Synthesis and Analysis
Findings for each KQ were qualitatively synthesized by summariz-
ing the characteristics and results of included studies in tabular or
narrative format. To determine whether meta-analyses were ap-
propriate, the clinical andmethodological heterogeneity (in popu-
lation, interventions, and outcomes) of the studies were assessed
following established guidance.4
Results
A total of 5786 titles and abstracts and 757 full-text articles were
screened (Figure 2). Of the 32 good- or fair-quality articles on pri-
mary studies or systematic reviews, 205-24 addressed KQ1a, 36,7,20
addressed KQ1b, 86,7,17-22 addressed KQ1c, 208-13,15,23-35 addressed
KQ2a, and625-27,33,35,36 addressedKQ2b.Becauseof theheteroge-
neity across studies and over time, results were not pooled.
Benefits of Folic Acid Supplementation
KeyQuestion 1a.Towhatextentdoes folic acid supplementation re-
ducetheriskforNTDs(firstoccurrence) inwomenofchildbearingage?
A total of 20 publications were found on the question of ben-
efits of folic acid supplementation. Seven publications present re-
sults of theonly eligibleRCT.8-13,15 The study, conducted inHungary,
was an RCT initiated in 1984 and terminated in 1992,with informa-
tion collected through 1993. Three publications relate to 2 cohort
studies; onewas aHungarian cohort study ofwomen recruited be-
tween 1993 and 1996,14 and the second was a cohort drawn from
womenwho underwent α-fetoprotein screening or amniocentesis
between1984and1987.18,19Allotherstudieswerecase-control stud-
iesandcompared infantshavingNTD-associatedmalformationswith
nonmalformed infants5-7,17,20,21 or with infants having non–NTD-
associatedmalformations.16,22 Additionally, we checked the previ-
ous update to ensure that we had rereviewed and included all pre-
viously evaluated studies if they continued to meet inclusion
criteria.23,24
These 20publications, comprising 11 primary studies and 1 sys-
tematic review,23,24drewfrom8data sources (Hungarian trial,8-13,15
Hungarian cohort,14 the New England study,18,19 the National Birth
DefectsPreventionStudy,5,6 theSloneBirthDefectsStudy,7,16,22 the
National InstituteofChildHealthandHumanDevelopment (NICHD)
Neural Tube Defects Study,17 the California Birth Defects Monitor-
ing Program,20 and the Texas Department of Health’s Neural Tube
Defect Project21). Together they span births occurring over 3 de-
cades, from 1976 through 2007.
AlthoughtheRCTandthecohortstudiespotentiallyoffergreater
controls for potential sources of bias, they predate the 1998 regu-
lationsonmandatoryfoodfortification intheUnitedStates.Thecase-
control studies span a period ranging from 1976 through 2008, in-
cluding several relying exclusively on data collected after food
fortification. These 8 publications of case-control data draw from
related, or in some cases subsets, of the same data.
Because study design, source of data, and secular changes in
food fortificationover time can all influence interpretationof study
findings, results arepresented first by studydesign, secondbydata
source (presentingnational ormultistate aheadof 2-stateor single-
state studies), and third by date of data collection for each publica-
tion for a data source.
Evidence From Trials
OneRCT,described in7publications,8-13,15 randomized5453women
in Hungary preconceptionally to a vitamin supplement containing
folic acid or a trace-element supplement (Table 1). The trial re-
ported no cases of NTDs in the experimental group and 6 cases in
the control group (0%vs 0.25%; 25 fewer cases per 10000 [95%
CI, 3-47 fewer]; P = .01 by Fisher exact test; Peto odds ratio [OR],
0.13 [95% CI, 0.03-0.65]).
Evidence From Cohort Studies
At the conclusion of the RCT described above, no additional RCT
was considered ethically possible because of the clear benefits of
folic acid supplementation. The authors continued their investiga-
tion using the same intervention in a cohort of 6112 women drawn
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from the Hungarian Periconceptional Service (1993 to 1996), with
supplementation provided before conception (Table 1).14 When
compared with outcomes for unsupplemented pregnant women,
the adjusted OR of an NTD-affected pregnancy for supplemented
women was 0.11 (95% CI, 0.01-0.91; 0% vs 0.29%; 29 fewer cases
per 10 000 [95% CI, 9-50 fewer]).14 A cohort study of 23 491
women in New England undergoing α-fetoprotein screening or
amniocentesis between weeks 15 and 20 of gestation (1984 to
1987) defined exposure as the use of at least 1 multivitamin con-
taining folic acid per week, between weeks 1 and 6 following con-
ception (Table 2). Use of multivitamins containing folic acid was
associated with an OR for NTD-affected pregnancy of 0.27 (95%
CI, 0.11-0.63; 0.09% vs 0.35%, 26 fewer cases per 10000 [95%
CI, 4-47 fewer]).18
Figure 2. Literature Search FlowDiagram
34 Articles (30 studies) excluded
(high or unclear risk of bias)
20 Articles included for KQ1a 3 Articles included for KQ1b
5029 Excluded after review of titles
and abstracts
691 Excludeda
270 Wrong publication type or not
original research
28 Wrong publication
15 Wrong comparator
124 Wrong outcome
2 Wrong timing
36 Wrong geographical setting
44 Wrong study design
98 Wrong intervention
1 Wrong sample size
68 Wrong language or non-English
5 Article irretrievable
8 Articles included for KQ1c 20 Articles included for KQ2a 6 Articles included for KQ2b
66 Articles (54 studies) eligible
3364 Duplicates removed
757 Full-text articles assessed for eligibility
5786 Records screened
2710 PubMed
1319 ClinicalTrials.gov
1221 EMBASE
363 Cochrane
105 WHO ICTRP
62 NIH Reporter
5 HSRProj
1 Suggestions from public
comments
5879 Records identified through
database searching
3255 PubMed
1958 EMBASE
666 Cochrane
3271 Records identified through
other sources
3022 ClinicalTrials.gov
127 NIH Reporter
116 WHO ICTRP
5 HSRProj
1 Suggestions from public
comments
32 Articles (24 studies) included in
qualitative synthesis of systematic review 
KQ indicates key question.
a Reasons for exclusion: Wrong publication type/not original research: Study
was not original research or systematic review. Wrong population: Study was
not conducted in an eligible population. Wrong comparator: Study did not
include eligible comparators or had no comparators. Wrong outcome: Study
did not include eligible outcomes or had no outcomes. Wrong timing: Study
did not examine supplementation before index pregnancy or during the first
trimester. Wrong geographic setting: Study was not conducted in a country
relevant to US practice (very high human development index). Wrong study
design: Study did not include an eligible design. Wrong intervention: Study did
not include an eligible intervention or had no intervention. Wrong sample size:
Study had 50 or fewer participants. Wrong language/non-English: Study was
not published in English. Article irretrievable: Study could not be retrieved.
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Evidence From Case-Control Studies
Case-control studies included multistate, 2-state, and single-state
sources (Table2). Two includedpublicationsused theNationalBirth
Defects Prevention Study,5,6 whichwas established in 1997 and in-
cludes population-based birth defects surveillance systems in 10
sites. Eight of 10 surveillance sites include live births, fetal deaths,
and elective pregnancy terminations, thus mitigating, but not en-
tirely eliminating, the risk of selection bias.5Womenwere asked to
recall use of multivitamins or supplements from 3 months before
pregnancy through the lastmonthofpregnancy, resulting inamaxi-
mumrecallperiodof3years.Bothpublicationsareconsistent indem-
onstrating a lack of association of folic acid supplementation with
benefits (adjustedOR for anencephaly and spina bifida, 0.93 [95%
CI,0.82-1.06]5;adjustedORforanencephaly, 1.2 [95%CI,0.8-1.9]5,6).
Three includedstudieswerebasedondata fromtheSloneBirth
Defects Studyandwerepublished in 1993,22 2001,16 and2011.7 The
Slone Birth Defects Study began in 1976. It identified cases, largely
from hospital discharge records; randomly selected controls; and
identified exposure to folic acid supplements through an interview
conductedwithin 6months of delivery going back to 6months be-
fore pregnancy. Over the course of several decades, the list of in-
cluded sites and sources changed. The definition of exposure var-
ied by publication, and the period of recall ranged from 15 to 17
months. The 1993and2001publications reliedondata fromtheera
before food fortification and consistently demonstrated that daily
use of supplements was associated with a lower risk of NTDs com-
pared with nonuse (adjusted OR of 0.7 [level of precision here and
belowas reportedbyauthors] [95%CI,0.5-0.8] in the2001study16;
adjustedORof0.6 [95%CI,0.4-0.8] in the 1993 study22). The2011
SloneBirthDefects Study foundno association of folic acid supple-
mentation with the risk of spina bifida, regardless of the level of
supplementation.7
Two other studies were conducted in the era before food for-
tification. Both studies drew on data from the California Birth De-
fectsMonitoringprogram,usingcases from1985to 198717 and 1989
to1991.20Onestudyadditionallydrewondata fromIllinois (also from
1985 to 1987, the NICHDNeural Tube Defects Study).17 Recall peri-
ods ranged from 13 to 17 months. The NICHD Neural Tube Defects
Study reportednoassociationof supplementswithNTDs (OR, 1.00
[95% CI, 0.73-1.40]; P = .97).17 The study of California-only data
foundanORof0.65 (95%CI,0.45-0.94) for anyuse in the3months
before conception.20
Onecase-control studyfroma limiteddatasourcecollecteddata
from January 1995 to February 1999 from 148 Mexican American
women living along the Texas-Mexico border with NTD-affected
pregnancies and 158 control women with normal live births.21 The
averageperiodof recall for thisstudywas13months.Thestudy,span-
ning the eras before andafter food fortification, foundanonsignifi-
cant protective OR for NTDs (0.77 [95% CI, 0.19-3.22]) in the sub-
set of women taking multivitamins containing folic acid daily for 3
monthsor lessprior to conception;whenadjusted formaternal age,
education, obesity, andprevious stillbirth ormiscarriage, the direc-
tion of effect altered (adjusted OR, 1.12 [95%CI, 0.22-5.78; P value
not reported).
Key Question 1b. Does the effect of folic acid supplementation on
NTDs (first occurrence) differ by race or ethnicity?
Three case-control studies provide limited information about
the effects of folic acid supplementation by racial and ethnic char-
acteristics (eTable 6 in the Supplement).6,7,20 The Slone Birth De-
fects Study (1998 to2008) foundnopositive associationwithperi-
conceptional folic acid supplementation for white women and a
possible increased risk of spina bifida among consistent supple-
ment users of Hispanic ethnicity when compared with nonusers7;
however, the authors note that this finding may be attributable to
chance.
The National Birth Defects Prevention Study (1998 to 2003)
foundthatpericonceptional supplementusewasnotassociatedwith
a lowerriskofhavingapregnancyaffectedbyanNTD,andtherewere
no differences in the effects of folic acid supplementation by race
orethnicity.6TheCaliforniaBirthDefectsMonitoringProgramStudy
foundthatwomenwhousedany folic acid–containingvitamin in the
3 months before conception had a lower risk of having an NTD-
affectedpregnancy.20Reduction in risk forHispanicswasof smaller
magnitude than that observed for non-Hispanicwhites andblacks,
but these resultswerenot statistically significant andcouldhaveoc-
curred because of chance.
KeyQuestion 1c.Do the benefits of folic acid supplementation dif-
fer by dosage, timing, or duration of therapy?
One cohort study18,19 and 6 case-control studies6,7,17,20-22 pro-
vided information on the effects of dosage (eTable 7 in the
Supplement) and timing (eTable 8 in the Supplement) of folic acid
supplementation on NTDs. Four studies (1 cohort study19 and 3
case-control studies17,20,22) reported on dose of folic acid supple-
mentation. Five studies (1 cohort study18 and 4 case-control
studies6,7,20,21) reported on timing of folic acid supplementation. All
included studies on dose predate the food-fortification era17,19,20,22
and generally failed to find a dose-response effect. An exception
was the Slone Birth Defects Study (1988 to 1991),22 which sug-
gested lower odds of NTDswith daily use vs less than daily use (OR,
0.57 [95% CI, 0.35-0.93]). Older studies on timing consistently
show no effect, whereas newer studies varied, with 1 study
(postfortification)6 showing a protective association with use
before pregnancy on anencephaly but not spina bifida and the
other not finding a protective association for spina bifida.7
Harms of Folic Acid Supplementation
KeyQuestion2a.Are thereharmsassociatedwith folic acid supple-
mentation to themother, fetus, neonate, or child?
One RCT11 and 1 cohort study31 provided information on twin-
ning (Table 3). In aHungarian trial comparing folic acid supplemen-
tationwithamultivitamintotraceelementsamong informativepreg-
nancies (definedas livebirths and stillbirths [late fetal deaths]), the
proportion of twin pregnancies and twinbirthswas not statistically
significantly different between the 2 groups. Of the total pregnan-
cies in themultivitamin group, 1.9% (46/2421)were determined to
be twin gestations, compared with 1.4% (32/2346) of pregnancies
in the trace element group (OR, 1.40 [95%CI, 0.89-2.21]; 54more
cases per 10000 [95% CI, 18 fewer to 125more]). The proportion
of twin births (as opposed to pregnancies) was higher in themulti-
vitamin group (93/2468 [3.8%]) than in the trace element group
(64/2378 [2.7%]; OR, 1.41 [95% CI, 1.03-1.96]; 108more cases per
10000 [95% CI, 8 more to 207 more]). In a subgroup analysis of
womenreceiving fertilitydrugs, the trial foundnodifference in twin-
ning between the 2 groups.11 A prospective cohort study found an
increased odds (baseline adjustment for maternal age and parity)
of twinningamongpregnancieswith folateusecomparedwith those
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withnofolatesupplementation.31Withfurtheradjustment for invitro
fertilization, theoddswereattenuatedandno longer statistically sig-
nificant (1.04 [95% CI, 0.91-1.18]).
Eight articles25,27-30,32,33,36 synthesized in 3 systematic
reviews26,34,35 reportedon respiratoryharms (childhoodasthmaor
wheezingandallergen-relatedoutcomes).All includedprimarystud-
ieswereobservational,with attendant risksofmisclassificationand
recall bias. The pooled estimate from 1meta-analysis26 focusing on
the prepregnancy period through the first trimester (N not re-
ported) found no evidence from 3 studies29,30,32 of an association
betweenmaternal folic acidsupplementationcomparedwithnouse
and childhood asthma, with a pooled relative risk of 1.01 (95% CI,
0.78-1.30; P = .95; I2 = 0.00; P = .73).26 A second meta-analysis
(n = 14 438)34 included5 studies25,29,30,32,33 and foundnoassocia-
tion between folic acid supplementation during the periconcep-
tionalperiodorpregnancyandthedevelopmentofchildhoodasthma
(OR, 1.06 [95% CI, 0.99-1.14]) but reported wide variations in the
dose of folic acid supplementation across included studies. A third
meta-analysis,35consistingofasubsetof theprimarystudies inother
meta-analyses, also reported no statistically significant association
of folic acid supplementation with asthma, wheezing, atopic der-
matitis, eczema, and sensitization.
Onetrial13 also reportedonpotential adverseeffectsof folic acid
supplementation, many of which are common pregnancy symp-
toms, such as weight gain, gastrointestinal symptoms, and rashes.
The study foundnostatistically significantdifferences in the report-
ing of most of these symptoms between the 2 groups from before
pregnancy through pregnancy confirmation.
KeyQuestion2b.Do theharmsof folic acid supplementationdiffer
by dosage, timing, or duration of therapy?
One study separated the study population into tertiles of fo-
late taken as vitamin supplements (<0.2mg/d, 0.2 to 0.499mg/d,
and0.5mg/d) and compared the second and third tertiles to the
first for the incidence of any allergic disease, sensitization, recur-
rent wheezing, eczema, food reactions, IgE-mediated food allergy,
and sensitization to foodallergens (eTable9 in theSupplement). All
results had wide confidence intervals spanning or overlapping the
line of no difference.36
Two of the cohort studies included in a previously published
meta-analysis26 examined the association between prenatal use of
a supplement containing folic acid (compared with no use) in the
second or third trimester and asthma or wheezing in childhood
(eTable 10 in the Supplement).25,27 Of the 15 associations evaluated
across 2 studies, only 1 association was significantly increased (ad-
justed prevalence ratio for maternal report of wheezing at 1 year,
1.20 [95% CI, 1.04-1.39]).25 Three cohort studies examined the use
of supplements containing folic acid during the second or third tri-
mester and risk of other allergic outcomes.25,27,33 The meta-
analysis reported no significant findings in 38 reported associations
across these 3 studies.26
A meta-analysis examined the incidence of asthma and
wheezing by timing of supplementation (prepregnancy, early
pregnancy, other period in pregnancy).35 Four of 5 reported asso-
ciations showed no statistically significant association of folic acid
supplementation with asthma or wheezing in childhood. The 1
statistically significant association with wheezing in childhood
was associated with exposure in early pregnancy (relative risk,
1.06 [95% CI, 1.02-1.09]).27-29
Discussion
A summary of findings in this evidence review is found in Table 4
and Table 5. Most of the studies included in this review have
broad eligibility criteria; their participants are representative of
the US primary care population. Early studies (1 trial, cohort and
case-control studies) provided consistent evidence of benefit.
After the publication of the Hungarian trial and other trials in
women with recurrent NTDs (not included in this review), the evi-
dence of benefit pointed to the need for large-scale public health
interventions; the United States initiated the addition of folate to
grain products in 1998.41 The evidence of benefit also made the
conduct of additional trials unethical. As a consequence, all sub-
sequent studies relied on observational data using case-control
designs. These case-control studies do not show a protective
association.
Therewasnoconsistentevidenceofvariation inbenefits forsub-
populations or by dose or timing. Therewas also no consistent evi-
dence of an increased risk of twinning or childhood respiratory ill-
nesses or variation in these outcomes by timing or dose.
Although the effect of food fortification may explain lack of
benefit in more recent studies, study design flaws and inadequate
sample size in these studies are also important considerations. All
included observational studies in this review contain inherent and
unavoidable sources of bias. Prospective cohort studies may not
be able to ascertain all NTD cases. Retrospective studies have a
risk of recall bias. In the case-control studies included in this
review, women were asked to recall frequency and dose of
supplements over a relatively short period of exposure (around
the time of conception) occurring between 13 months and 3 years
prior to the interview. Both of the risks of bias described above
(case ascertainment and recall) will reduce the differences
between study groups. The relative rarity of the outcome and the
difficulty of adequately powering studies also complicates the
interpretation of the results.
An additional consideration in weighing the relative contribu-
tions of folic acid supplementation and food fortification is the
extent of benefit provided by food fortification. Estimates of
folate sufficiency of intake vary widely by measure. When the
highest threshold, the recommended usual intake of 0.4 mg/d, is
used, National Health and Nutrition Examination Survey data
from 2003 to 2006 suggest that 76% of nonpregnant women
aged 15 to 44 years did not consume the recommended daily
intake. Among all women, the median intake of folic acid overall
was 0.245 mg/d.42 The proportion of women not consuming the
recommended usual intake varies from 70 to 91% by race and
ethnicity.
Rather than using a daily 400-μg dosage to define adequate
intake, another approach is to set the threshold for insufficiency
based on red blood cell folate concentrations. A threshold of
400 ng/mL (906 nmol/L) or more is based on an association of
the threshold with an NTD prevalence of more than 9 per 10000
live births. This threshold yields an estimate suggesting a lower
level of insufficiency, on average, with 22.8% of nonpregnant
women aged 12 to 49 years having suboptimal red blood cell
folate concentrations for NTD prevention.43 Levels vary by use of
dietary supplements containing folic acid, consumption of man-
Evidence Report: Folic Acid Supplementation to Prevent Neural Tube Defects US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA January 10, 2017 Volume 317, Number 2 199
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Ta
bl
e
4.
Su
m
m
ar
y
of
Ev
id
en
ce
fo
rB
en
ef
its
of
Fo
lic
Ac
id
Su
pp
le
m
en
ta
tio
n
(K
ey
Q
ue
st
io
n
1)
N
o.
of
St
ud
ie
s
(S
tu
dy
De
si
gn
s)
,
N
o.
of
Pa
rt
ic
ip
an
ts
Su
m
m
ar
y
of
Fi
nd
in
gs
Co
ns
is
te
nc
y/
Pr
ec
is
io
n
Re
po
rt
in
g
Bi
as
O
ve
ra
ll
Q
ua
lit
y
Bo
dy
of
Ev
id
en
ce
Li
m
ita
tio
ns
As
se
ss
m
en
to
fS
tr
en
gt
h
of
Ev
id
en
ce
fo
rK
ey
Q
ue
st
io
n
Ap
pl
ic
ab
ili
ty
Ke
y
Q
ue
st
io
n
1a
:E
xt
en
tt
o
W
hi
ch
Fo
lic
Ac
id
Su
pp
le
m
en
ta
tio
n
Re
du
ce
st
he
Ri
sk
fo
rN
TD
s
12 (1
RC
T,
8
-1
3
,1
5
2
co
ho
rt
st
ud
ie
s,
1
4
,1
8
,1
9
8
ca
se
-c
on
tr
ol
st
ud
ie
s,
5
-7
,1
6
,1
7
,2
0
-2
2
1
sy
st
em
at
ic
re
vi
ew
2
3
,2
4
);
N
>
41
80
2
RC
T
(p
re
fo
rt
ifi
ca
tio
n)
:P
et
o
O
R
fo
rN
TD
s,
0.
13
(9
5%
CI
,0
.0
3-
0.
65
;P
=
.0
1)
8
-1
3
,1
5
Co
ho
rt
st
ud
ie
s(
pr
ef
or
tif
ic
at
io
n)
:a
dj
us
te
d
O
R
fo
rN
TD
s,
0.
11
(9
5%
CI
,0
.0
1-
0.
91
)1
4
;
O
R
fo
rN
TD
s,
0.
27
(9
5%
CI
,
0.
11
-0
.6
3)
.1
8
,1
9
Ca
se
-c
on
tr
ol
st
ud
ie
s(
pr
ef
or
tif
ic
at
io
n)
:
re
su
lts
in
cl
ud
e:
ad
ju
st
ed
O
R
fo
rN
TD
s,
0.
7
(9
5%
CI
,0
.5
-0
.8
)1
6
;a
dj
us
te
d
O
R
fo
r
NT
Ds
,0
.6
(9
5%
CI
,0
.4
-0
.8
)2
2
;O
R
fo
r
NT
Ds
,0
.6
5
(9
5%
CI
,0
.4
5-
0.
94
)2
0
;O
R
fo
r
NT
Ds
,1
.0
0
(9
5%
CI
,0
.7
3-
1.
43
)1
7
Ca
se
-c
on
tr
ol
st
ud
ie
s(
sp
an
ni
ng
pr
ef
or
tif
ic
at
io
n
an
d
po
st
fo
rt
ifi
ca
tio
n)
:
ad
ju
st
ed
O
R
fo
rN
TD
s,
1.
12
(9
5%
CI
,
0.
22
-5
.7
8)
2
1
Ca
se
-c
on
tr
ol
st
ud
ie
s(
po
st
fo
rt
ifi
ca
tio
n)
:O
R
fo
rN
TD
s,
1.
11
(9
5%
CI
,0
.7
4-
1.
65
)f
or
co
ns
is
te
nt
us
er
s7
;a
dj
us
te
d
O
R
fo
rN
TD
s
(a
ne
nc
ep
ha
ly
+
sp
in
a
bi
fid
a)
,0
.9
3
(9
5%
CI
,0
.8
2-
1.
06
)5
;a
dj
us
te
d
O
R
fo
r
an
en
ce
ph
al
y,
1.
2
(9
5%
CI
,0
.8
-1
.9
)6
;
ad
ju
st
ed
O
R
fo
rs
pi
na
bi
fid
a:
1.
4
(9
5%
CI
,
1.
0-
1.
8)
6
Co
ns
is
te
nc
y:
ge
ne
ra
lly
co
ns
is
te
nt
w
ith
in
th
e
pr
ef
or
tif
ic
at
io
n
an
d
po
st
fo
rt
ifi
ca
tio
n
er
as
,
in
co
ns
is
te
nt
ov
er
tim
e
Pr
ec
is
io
n:
w
id
e
CI
sb
ut
cl
ea
r
in
di
ca
tio
n
of
be
ne
fit
in
th
e
pr
ef
or
tif
ic
at
io
n
er
a,
na
rr
ow
er
CI
sw
ith
CI
s
sp
an
ni
ng
th
e
nu
ll
in
po
st
fo
rt
ifi
ca
tio
n
er
a
Un
de
te
ct
ed
Fa
ir
No
ne
w
tr
ia
ls
ca
n
be
co
nd
uc
te
d
on
th
is
to
pi
c.
Ne
w
st
ud
ie
sm
us
tr
el
y
on
ob
se
rv
at
io
na
ld
at
a
w
ith
in
he
re
nt
ris
ks
of
ca
se
as
ce
rt
ai
nm
en
tb
ia
s
(p
ro
sp
ec
tiv
e
co
ho
rt
st
ud
ie
s)
or
re
ca
ll
bi
as
(r
et
ro
sp
ec
tiv
e
st
ud
ie
s)
Hi
gh
fo
rp
re
fo
rt
ifi
ca
tio
n
da
ta
;
lo
w
fo
rp
os
tf
or
tif
ic
at
io
n
da
ta
Ge
ne
ra
lly
ap
pl
ic
ab
le
to
pr
im
ar
y
ca
re
Ke
y
Q
ue
st
io
n
1b
:D
iff
er
en
ce
si
n
Ef
fe
ct
of
Fo
lic
Ac
id
Su
pp
le
m
en
ta
tio
n
on
NT
Ds
by
Ra
ce
/E
th
ni
ci
ty
3 (3
ca
se
-c
on
tr
ol
st
ud
ie
s6
,7
,2
0
);
N
=
11
15
4
No
ef
fe
ct
in
on
e
st
ud
y6
;h
ig
he
rr
is
k
in
se
co
nd
(a
dj
us
te
d
O
R
fo
rN
TD
sf
or
Hi
sp
an
ic
w
om
en
,2
.2
0
(9
5%
CI
,0
.9
8-
4.
92
7
);
le
ss
pr
ot
ec
tiv
e
ef
fe
ct
in
th
ird
2
0
:r
is
k
re
du
ct
io
n
le
ss
m
ar
ke
d
fo
rH
is
pa
ni
c
w
om
en
(O
R
fo
r
NT
Ds
,0
.9
6
(9
5%
CI
,0
.4
4-
2.
10
)t
ha
n
no
n-
Hi
sp
an
ic
w
hi
te
s(
O
R
fo
rN
TD
s,
0.
62
(9
5%
CI
,0
.3
5-
1.
10
)o
rb
la
ck
s(
O
R
fo
r
NT
Ds
,0
.5
4
(9
5%
CI
,0
.0
9-
3.
20
)
In
co
ns
is
te
nt
Im
pr
ec
is
e
Un
de
te
ct
ed
Fa
ir
Sm
al
ln
um
be
rs
in
ea
ch
co
m
pa
ris
on
,
ef
fe
ct
sp
os
si
bl
y
du
e
to
ch
an
ce
Lo
w
Ge
ne
ra
lly
ap
pl
ic
ab
le
to
pr
im
ar
y
ca
re
Ke
y
Q
ue
st
io
n
1C
:D
iff
er
en
ce
si
n
Ef
fe
ct
of
Fo
lic
Ac
id
Su
pp
le
m
en
ta
tio
n
on
NT
Ds
by
Do
sa
ge
,D
ur
at
io
n,
an
d
Ti
m
in
g
Do
sa
ge
:4
(1
co
ho
rt
st
ud
y,
1
8
,1
9
3
ca
se
-c
on
tr
ol
st
ud
ie
s1
7
,2
0
,2
2
);
n
=
26
79
1
Du
ra
tio
n:
0
Ti
m
in
g:
5
(1
co
ho
rt
st
ud
y,
1
8
,1
9
4
ca
se
-c
on
tr
ol
st
ud
ie
s6
,7
,2
0
,2
1
);
N
=
26
80
8
No
in
di
ca
tio
n
of
do
se
re
sp
on
se
in
3
of
4
st
ud
ie
s.
O
ne
st
ud
y
sh
ow
sl
ow
er
od
ds
fo
r
da
ily
us
e
vs
le
ss
th
an
da
ily
us
e
(O
R
fo
r
NT
Ds
,0
.5
7
(9
5%
CI
,0
.3
5-
0.
93
)2
2
Du
ra
tio
n:
no
ne
Ti
m
in
g:
Ca
lc
ul
at
ed
O
R
fo
rN
TD
sf
ro
m
co
ho
rt
st
ud
y
fo
ru
se
w
k
1-
6
vs
w
k
7
an
d
la
te
r,
0.
29
(9
5%
CI
,0
.1
4-
0.
60
).1
8
,1
9
O
ld
er
ca
se
-c
on
tr
ol
st
ud
ie
sc
on
si
st
en
tly
sh
ow
no
ef
fe
ct
of
tim
in
g,
2
0
,2
1
1
ne
w
st
ud
y
(p
os
tf
or
tif
ic
at
io
n)
sh
ow
sa
pr
ot
ec
tiv
e
ef
fe
ct
of
us
e
be
fo
re
pr
eg
na
nc
y
on
an
en
ce
ph
al
y
bu
tn
ot
sp
in
a
bi
fid
a.
6
Th
e
ot
he
rn
ew
st
ud
y
di
d
no
tf
in
d
a
pr
ot
ec
tiv
e
ef
fe
ct
fo
rs
pi
na
bi
fid
a.
7
In
co
ns
is
te
nt
Im
pr
ec
is
e
Un
de
te
ct
ed
Fa
ir
Sm
al
ln
um
be
rs
in
ea
ch
co
m
pa
ris
on
,
ef
fe
ct
sp
os
si
bl
y
du
e
to
ch
an
ce
,s
tu
di
es
us
e
di
ff
er
en
tm
ea
su
re
so
fd
os
e
an
d
tim
in
g
Lo
w
Ge
ne
ra
lly
ap
pl
ic
ab
le
to
pr
im
ar
y
ca
re
Ab
br
ev
ia
tio
ns
:N
TD
,n
eu
ra
lt
ub
e
de
fe
ct
;O
R,
od
ds
ra
tio
;R
CT
,r
an
do
m
iz
ed
cl
in
ic
al
tr
ia
l.
Clinical Review& Education US Preventive Services Task Force Evidence Report: Folic Acid Supplementation to Prevent Neural Tube Defects
200 JAMA January 10, 2017 Volume 317, Number 2 (Reprinted) jama.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
datorily fortified enriched cereal grain products as the only source
of folic acid, non-Hispanic black or Hispanic race and ethnicity,
and current smoking status.
Very few women exceed the upper level for folic acid con-
sumption (1000 μg/d). According to the 2015 Dietary Guideline
Advisory Committee report, less than 3% of women aged 14 to
50 years were getting more than 1000 μg/d from food, bever-
ages, and dietary supplements, based on National Health and
Nutrition Examination Study data collected from 2007-2010.44
The limitations of this reviewarise from its scope and the limita-
tions of the evidence. As with the previous USPSTF review on this
topic,23,24 interventions were restricted to folic acid supplementa-
tionanddidnotevaluatetheeffectivenessof foodfortification,coun-
seling to increase dietary intake, or screening for NTDs. The review
Table 5. Summary of Evidence for Benefits or Harms of Folic Acid Supplementation (Key Question 2)
No. of Studies
(Study Designs) Summary of Findings Consistency/Precision
Reporting
Bias
Overall
Quality
Body of
Evidence
Limitations
Assessment
of Strength of Evidence
for Key Question Applicability
Key Question 2a: Harms Associated With Folic Acid Supplementation
Twinning in
women: 2
(1 trial,11
1 cohort31);
N = 7387
The trial found no
statistically
significant
differences in twin
pregnancy rate (OR
for twin pregnancy,
1.40 (95% CI,
0.89-2.21).11 The
cohort study31 found
that the higher risk of
twin birth for folic
acid supplementation
use (OR for twin
birth, 1.59 [95% CI,
1.41-1.78]) was
attenuated once
potential
misclassification was
accounted for (1.04
[95% CI,
0.91-1.18])31
Consistent
Imprecise
Undetected Fair Low event rate,
wide CIs
Moderate
for no effect
Generally
applicable to
primary care
Childhood
asthma,
wheezing,
allergy: 11
(3 systematic
reviews,26,34,35
8
observational
studies25,27-30,32,33,36);
N > 14 438
No effect for a large
majority of
comparisons and
outcomes25-30,32-36
Consistent
Precise
Undetected Variable
measures of
outcomes and
exposure, all
observation
studies with
risks of bias
from case
ascertainment
and recall
Moderate
for no effect
Generally
applicable to
primary care
Other adverse
events in
women: 1
(1 RCT13);
N = 4862)
Increased risk for
weight gain,
diarrhea,
constipation; reduced
risk for irregular
defecation; no
difference for
increased appetite,
lack of appetite,
exanthema,
heartburn, and
vertigo13
Consistency unknown,
single study, imprecise
Undetected Low event rate,
wide CIs
Low
for no effect
Generally
applicable to
primary care
Key Question 2b: Differences in Harms Associated With Folic Acid Supplementation by Dosage, Timing, and Duration
Dosage: 2
(1 systematic
review,26
1
observational
study36);
N = 484
Duration: 0
Timing of
asthma,
wheezing,
allergy: 5
(2 systematic
reviews,26,35
3
observational
studies25,27,33);
No. varies by
outcome
Dosage: no
consistent increase in
the risk of childhood
asthma, wheezing, or
allergies by
dosage26,36
Duration: none
Timing: no consistent
increase in the risk of
childhood asthma,
wheezing, or
allergies by
timing25-27,33,35
Consistent
Precise
Undetected Variable
measures of
outcomes and
exposure, all
observation
studies with
risks of bias
from case
ascertainment
and recall
Low
for no effect
Generally
applicable to
primary care
Abbreviations: NTD, neural tube defect; OR, odds ratio; RCT, randomized clinical trial.
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did not examine the effects of folic acid supplementation on ben-
efitsother thanavertedNTDs. Inaddition, itdidnotevaluatesystem-
atically theeffectof folicacidsupplementationamonghigh-riskpopu-
lations such aswomenwith previous pregnancies with NTDs.
Limitations of the evidence relate to insufficient data and the
quality of evidence as a whole. There was very limited information
ondifferences inbenefits and risksof folic acid supplementationby
race, ethnicity, dose, and timingandno informationonduration.Re-
garding the overall quality of evidence, ethical considerations limit
the conduct of RCTs for this question.
Conclusions
In studies conducted before the initiation of food fortification in
the United States in 1998, folic acid supplementation provided
protection against neural tube defects. Newer postfortification
studies have not demonstrated a protective association but have
the potential for misclassification and recall bias, which can
attenuate the measured association of folic acid supplementation
with neural tube defects.
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